Spanish for head and neck oncology clinic nurses — the oropharyngeal cancer patient who cannot understand why chemoradiation is recommended when the tumor is visible and the surgeon could remove it, the thyroid cancer patient who cannot understand why active surveillance is recommended for a confirmed cancer, and the laryngeal cancer family who cannot understand why radiation preserves the voice when surgery could remove the tumor

The head and neck oncology clinic’s communication challenge

Head and neck oncology nurses work at the intersection of two patient experiences that create specific, predictable communication failures: the patient can often see or feel the tumor (a neck mass, a palpable lump under the jaw, a visible lesion on laryngoscopy), and the treatment recommendation frequently does not involve directly removing it.

In most of oncology, the model holds: a visible, biopsy-confirmed tumor is removed. The surgeon cuts it out, sends the specimen to pathology, and the treatment is the surgery. Head and neck oncology has three major categories where this model breaks down — not because surgery is unavailable or technically impossible, but because the evidence shows something different gives the same or better survival with less functional damage: HPV-positive oropharyngeal cancer, papillary thyroid microcarcinoma, and resectable laryngeal cancer.

Each departure from surgery has a different clinical reason. In HPV-positive oropharyngeal cancer, the reason is biological: HPV-driven tumors are exquisitely radiosensitive, surgical access to the oropharynx requires functional morbidity from TORS or mandibulotomy, and ORATOR2 showed that radiation achieves equivalent survival with better patient-reported swallowing. In papillary thyroid microcarcinoma, the reason is natural history: the Kuma Hospital data followed over 1,200 patients for up to 25 years and found near-zero cancer-specific mortality even without surgery, while hemithyroidectomy carries real risks of permanent voice and calcium damage that exceed the benefit. In resectable laryngeal cancer, the reason is functional: the VA Laryngeal Cancer Study and RTOG 91-11 together established that concurrent chemoradiation achieves equivalent locoregional control to total laryngectomy while preserving the larynx in most patients — and total laryngectomy means permanent stoma, permanent loss of nasal breathing, and permanent loss of the natural voice.

For each of these patients, the nurse has to explain not just what the treatment is but why the evidence-based recommendation departs from the model the patient brought to the appointment. Three Spanish-language clinical encounters that turn on this explanation:

Scenario 1: Javier Morales — 54, construction manager from Los Angeles, HPV-positive T2N2b squamous cell carcinoma of the right tonsil

Javier Morales is fifty-four years old, a construction project manager from East Los Angeles who has lived in the United States since he was eleven. He is a nonsmoker who drinks alcohol socially and in twenty years of health visits has been otherwise unremarkable. He presented to his primary care physician eight weeks ago with a firm, non-tender lump in the right side of his neck that he initially assumed was a swollen lymph node from a cold. It did not go away. His PCP obtained a neck ultrasound followed by fine-needle aspiration of the enlarged node, which returned poorly differentiated squamous cell carcinoma. He was referred to head and neck surgery, where flexible laryngoscopy identified a 2.2 centimeter primary tumor at the right tonsillar fossa with involvement of the anterior tonsillar pillar. MRI of the neck confirmed the tonsillar primary, multiple right-level-II and right-level-III lymph nodes up to 3.1 centimeters, and no evidence of carotid encasement or base-of-skull involvement. CT of the chest and abdomen was negative for distant metastases. Tumor p16 immunohistochemistry was strongly positive (greater than 70 percent nuclear and cytoplasmic staining), consistent with HPV-related disease. He was staged T2N2b (AJCC 8th edition Group I — low-risk HPV-positive). He was referred to the head and neck oncology multidisciplinary clinic.

At the head and neck oncology clinic, Javier arrived with his wife Margarita and their twenty-three-year-old daughter Ana, who had done research on her phone the night before. The oncology team recommended definitive concurrent chemoradiation: intensity-modulated radiotherapy (IMRT) to 70 Gray over seven weeks concurrent with weekly cisplatin 40 mg/m². No surgery.

Margarita spoke first: “¿Por qué no lo operan? El tumor está en la garganta. El doctor lo vio. ¿No pueden quitarlo?” (Why don’t they operate? The tumor is in the throat. The doctor saw it. Can’t they remove it?)

Head and neck oncology clinic nurse Patricia Vargas had expected this question. It was, in her experience, the question every family asked when the recommendation was chemoradiation for a tumor the laryngoscopist had reported as “clearly visible.”

“La pregunta tiene mucho sentido,” she said. “Cuando hay un tumor que el médico puede ver, la expectativa natural es que un cirujano lo puede quitar. Lo que quiero explicarles es por qué el cáncer de su esposo — específicamente el tipo causado por el VPH — responde diferente.” (The question makes a lot of sense. When there is a tumor the doctor can see, the natural expectation is that a surgeon can remove it. What I want to explain is why your husband’s cancer — specifically the type caused by HPV — responds differently.)

She began with the p16 result. Javier’s tumor was p16-positive, which is a surrogate marker for HPV-related disease. In the United States, approximately 70 percent of oropharyngeal squamous cell carcinomas are now HPV-related, and the proportion has been rising steadily since the 1990s. HPV-related oropharyngeal cancer is a biologically distinct entity from the smoking-and-alcohol-related oropharyngeal cancer that dominated the disease for the prior century. The biological distinction has oncological consequences: HPV-positive oropharyngeal cancer is exquisitely sensitive to both radiation and platinum-based chemotherapy. The virus integrates into the host genome in a way that activates p53 and Rb degradation pathways, and this genomic instability makes the tumor cells significantly more vulnerable to radiation-induced DNA damage than the smoking-related counterpart.

“Las células del cáncer que tiene usted — las células positivas para el VPH — son muy sensibles a la radioterapia,” Patricia explained. “Lo que hace la radiación es dañar el ADN de las células. Las células normales tienen mecanismos para reparar ese daño. Las células del cáncer causado por el VPH tienen ese mecanismo de reparación comprometido por el virus. Cuando la radiación daña el ADN de esas células, no lo pueden reparar y mueren. Eso es por qué la radioterapia para este tipo de cáncer específico logra tasas de control local del 90 porciento o más.” (The cancer cells you have — the HPV-positive cells — are very sensitive to radiotherapy. What radiation does is damage the DNA of cells. Normal cells have mechanisms to repair that damage. Cancer cells caused by HPV have that repair mechanism compromised by the virus. When radiation damages the DNA of those cells, they cannot repair it and they die. That is why radiotherapy for this specific type of cancer achieves local control rates of 90 percent or more.)

Ana, who had been taking notes, looked up: “¿Y la cirugía no daría los mismos resultados?” (And wouldn’t surgery give the same results?)

This was the core question, and Patricia answered it directly with the ORATOR2 data. The ORATOR2 trial, published in Lancet Oncology in 2022, was specifically designed to answer whether transoral robotic surgery (TORS) plus neck dissection or definitive radiotherapy with or without chemotherapy gave equivalent outcomes for patients with T1-2 N0-2 HPV-positive oropharyngeal cancer — exactly Javier’s disease. Two hundred and sixty-one patients were randomized. Two-year overall survival: 95.2 percent in the radiotherapy arm, 93.8 percent in the TORS arm — statistically equivalent. But patient-reported swallowing outcomes at two years, measured with the MD Anderson Dysphagia Inventory (MDADI) — a validated questionnaire specifically designed to capture how patients feel about their swallowing function — were significantly better in the radiotherapy arm.

“El estudio comparó exactamente lo que estamos discutiendo,” Patricia said, opening the clinic’s tablet to show them the ORATOR2 survival curves. “261 pacientes con el tipo de cáncer de su esposo — T1-2, positivo para el VPH, con ganglios. La mitad tuvo cirugía robótica más disección del cuello. La otra mitad tuvo radioterapia. La supervivencia a dos años fue prácticamente igual — 95 porciento contra 94 porciento. Pero los pacientes que tuvieron radioterapia reportaron mejor función para tragar a los dos años. Eso no es trivial — la función de tragar afecta qué puede comer, cómo se siente en las comidas con la familia, su calidad de vida en general.” (The study compared exactly what we are discussing. 261 patients with your husband’s type of cancer — T1-2, HPV-positive, with nodes. Half had robotic surgery plus neck dissection. The other half had radiotherapy. Survival at two years was practically equal — 95 percent vs. 94 percent. But patients who had radiotherapy reported better swallowing function at two years. That is not trivial — swallowing function affects what you can eat, how you feel at family meals, your overall quality of life.)

She explained why surgery for oropharyngeal cancer carries functional morbidity that radiation does not. Transoral robotic surgery accesses the tonsil and base of tongue through the mouth using robotic arms inserted transorally, sometimes requiring jaw-splitting approaches for full access. For Javier’s T2 primary, TORS would resect the tonsillar complex including the adjacent soft palate and tonsillar pillars with negative margins, followed by bilateral neck dissection to address the nodal disease. Because of his nodal burden (multiple positive nodes up to 3.1 cm), TORS would still be followed by adjuvant radiation — meaning he would receive both surgery and radiation, with the combined morbidity of TORS-related swallowing dysfunction and radiation-related xerostomia and mucositis. The ORATOR2 finding was specifically that this combined surgical-plus-radiation path produced worse swallowing outcomes than radiation-alone while achieving the same survival.

“El otro punto importante es que en el estadio de su esposo — con varios ganglios positivos — la cirugía sola no sería el tratamiento completo,” Patricia continued. “Después de la cirugía, con los ganglios que tiene, necesitaría radioterapia de todas maneras. Eso son dos tratamientos: la cirugía con sus complicaciones, y la radioterapia con las suyas. La radioterapia sola llega a la misma supervivencia sin sumar la morbilidad de la cirugía robótica.” (The other important point is that at your husband’s stage — with multiple positive nodes — surgery alone would not be the complete treatment. After surgery, with the nodes he has, he would need radiotherapy anyway. That is two treatments: surgery with its complications, and radiotherapy with its own. Radiotherapy alone achieves the same survival without adding the morbidity of robotic surgery.)

Javier had been quiet. Then he asked the question Patricia had been waiting for. “¿Qué significa VPH? ¿Es una enfermedad de transmisión sexual?” He glanced at Margarita. (What does HPV mean? Is it a sexually transmitted disease?)

Patricia did not hesitate. This question, unaddressed, could fracture the family’s engagement with the treatment plan. She had learned to answer it directly and immediately.

“El VPH es muy común,” she said. “La mayoría de los adultos en los Estados Unidos — más del 80 porciento — han tenido algún tipo de VPH en algún momento de su vida. El virus puede quedarse en el cuerpo por décadas sin dar síntomas. No es posible saber cuándo ni cómo se adquirió — puede haber sido hace veinte o treinta años. El cáncer de garganta causado por el VPH ha estado aumentando en los Estados Unidos desde los años 90. El VPH de garganta no dice nada sobre la fidelidad de nadie — eso es clínicamente cierto y es algo que les digo a todas las familias que enfrentan este diagnóstico.” (HPV is very common. Most adults in the United States — more than 80 percent — have had some type of HPV at some point in their life. The virus can stay in the body for decades without symptoms. It is not possible to know when or how it was acquired — it could have been twenty or thirty years ago. Throat cancer caused by HPV has been increasing in the United States since the 1990s. Throat HPV does not say anything about anyone’s fidelity — that is clinically true and it is something I tell every family facing this diagnosis.)

She told them that Javier’s children, if they had not already been vaccinated, should discuss HPV vaccination with their own primary care physicians. Vaccination in adolescence and young adulthood provides protection against the HPV strains associated with oropharyngeal cancer, cervical cancer, and other HPV-related malignancies. She did not recommend Margarita get tested — there is no clinical utility in testing partners of oropharyngeal cancer patients, and the test would not change the treatment of either patient.

Margarita exhaled. She had been holding the question for forty minutes. “Gracias por decir eso,” she said quietly. (Thank you for saying that.)

Patricia reviewed the treatment course: seven weeks of daily IMRT, Monday through Friday, concurrent with weekly cisplatin infusions. Response assessment at eight to twelve weeks with PET-CT. Acute side effects during treatment — mucositis, fatigue, skin changes, reduced saliva — were significant and manageable. Late effects — xerostomia, possible dysphagia, fibrosis — were reduced by the IMRT technique (which spares the parotid glands as much as possible) and by swallowing exercises started before and continued through treatment.

Javier completed seven weeks of chemoradiation. The mucositis was difficult in weeks five and six. He lost eighteen pounds and required enteral feeding support for four weeks. At twelve-week PET-CT there was no evidence of residual metabolically active disease. Swallowing therapy continued for three months post-treatment. At one-year follow-up his swallowing was functional for a regular diet. He remained cancer-free at two years. Ana, who had attended every single appointment, sent a message to the clinic: “Gracias por explicar desde el principio por qué la radiación era mejor. Mi papá no entendía por qué no iban a operar. Ahora lo entiende.” (Thank you for explaining from the beginning why radiation was better. My dad didn’t understand why they weren’t going to operate. Now he does.)

Key phrases for HPV-positive oropharyngeal cancer chemoradiation conversations

• “El cáncer de garganta causado por el VPH responde muy bien a la radioterapia — las células del tumor son mucho más sensibles a la radiación que en otros tipos de cáncer de cabeza y cuello.” (HPV-related throat cancer responds very well to radiotherapy — the tumor cells are much more sensitive to radiation than in other types of head and neck cancer.)
• “El estudio ORATOR2 comparó directamente la cirugía con la radioterapia en este tipo de cáncer. La supervivencia fue igual, pero los pacientes con radioterapia tuvieron mejor función para tragar a los dos años.” (The ORATOR2 study directly compared surgery with radiotherapy in this type of cancer. Survival was equal, but radiotherapy patients had better swallowing function at two years.)
• “Con los ganglios positivos que tiene, la cirugía sola no sería suficiente — necesitaría radioterapia de todas maneras. La radioterapia sola logra lo mismo sin sumar la cirugía.” (With the positive nodes he has, surgery alone would not be sufficient — he would need radiotherapy anyway. Radiotherapy alone achieves the same without adding surgery.)
• “El VPH es muy común en los adultos. No es posible saber cuándo se adquirió. No dice nada sobre la fidelidad de nadie.” (HPV is very common in adults. It is not possible to know when it was acquired. It says nothing about anyone’s fidelity.)
• “La radiación mata las células del tumor en su lugar. No necesita quitar físicamente el tumor cuando la radiación puede destruirlo con la misma eficacia.” (Radiation kills the tumor cells in place. You do not need to physically remove the tumor when radiation can destroy it with the same efficacy.)

Scenario 2: Elena Gutiérrez — 48, radiologist from Miami, incidental 8mm papillary thyroid microcarcinoma

Elena Gutiérrez is forty-eight years old, a diagnostic radiologist at a large academic medical center in Miami. She was born in Cuba, trained in medicine in Havana, emigrated in 2002, completed a radiology residency and fellowship in the United States, and has been reading cross-sectional imaging professionally for fifteen years. She is fluent in English and Spanish, reads medical literature regularly, and has ordered imaging on thousands of patients with thyroid nodules. She presented to endocrinology not because of a thyroid concern but because a parathyroid nodule was found incidentally on a neck CT obtained after she noticed hypercalcemia on routine labs. During the parathyroid ultrasound workup, the ultrasonographer also imaged the thyroid. A hypoechoic nodule with irregular margins was identified in the left thyroid lobe, measuring 8 millimeters. The characteristics were suspicious (TIRADS 5). Elena, as a radiologist, recognized immediately what the appearance meant. Fine-needle aspiration under ultrasound guidance returned: papillary thyroid carcinoma (Bethesda VI).

Elena came to her follow-up appointment with the head and neck oncology nurse prepared. She had read the American Thyroid Association guidelines. She had read several systematic reviews. She understood active surveillance in principle. But she had a confirmed biopsy of cancer. Every clinical instinct she had been trained to respect told her: confirmed cancer is treated, not watched.

“Entiendo los datos de Kuma,” she told nurse Diego Fuentes at the outset. “Los he leído. Pero eso es una base de datos japonesa con pacientes japoneses. ¿Por qué no me operan? Tengo cáncer confirmado con biopsia.” (I understand the Kuma data. I have read it. But that is a Japanese database with Japanese patients. Why don’t they operate on me? I have a biopsy-confirmed cancer.)

Diego recognized that the usual framing — building up to the Ito data as a revelation — would not work for Elena. She had already read the data. What she was asking was not “what does the evidence say” but “why does this evidence change the normal clinical logic?”

“Usted tiene razón en que el instinto médico normal dice que un cáncer confirmado se opera,” he began. “Eso es correcto para la mayoría de los cánceres. El microcarcinoma papilar de tiroides es la excepción clínica más estudiada a esa regla. Quiero explicar por qué, y también quiero ser honesto sobre los límites del argumento.” (You are right that the normal medical instinct says a confirmed cancer is operated on. That is correct for most cancers. Papillary thyroid microcarcinoma is the most studied clinical exception to that rule. I want to explain why, and I also want to be honest about the limits of the argument.)

He walked through the Kuma Hospital data in clinical specificity, because Elena was prepared to receive it that way. Dr. Akira Miyauchi and Dr. Yasuhiro Ito at Kuma Hospital in Osaka, Japan, began enrolling low-risk papillary thyroid microcarcinoma patients in an active surveillance protocol in 1993. Low-risk was defined as: PMC measuring 1 centimeter or less, no clinical evidence of lymph node metastases, no extrathyroidal extension, not immediately adjacent to the recurrent laryngeal nerve or the trachea on the posterior surface of the thyroid. Patients were followed with serial neck ultrasound every 6 to 12 months. Surgery was recommended if the tumor grew by 3 millimeters or more or if new suspicious lymph nodes appeared.

The 10-year outcomes, published in a series of papers in the Journal of Clinical Endocrinology and Metabolism, were: 3.8 percent of patients had size progression of 3 millimeters or more. 1.7 percent developed new clinical lymph node metastases. No patients (zero) developed distant metastases. No patients (zero) died of thyroid cancer. Cancer-specific survival was 100 percent at 10 years in over 1,200 patients followed with active surveillance.

“Eso es la parte que cambia el cálculo,” Diego said. “La mortalidad específica por cáncer a 10 años en 1,200 pacientes fue cero. No cercana a cero — cero. Y los que tuvieron progresión del tumor — el 3.8 porciento — fueron a cirugía entonces y sus resultados quirúrgicos fueron idénticos a los que hubieran sido operados al inicio. No se perdió ninguna ventana de curación por esperar.” (That is the part that changes the calculation. The cancer-specific mortality at 10 years in 1,200 patients was zero. Not near zero — zero. And those who had tumor progression — the 3.8 percent — went to surgery then, and their surgical outcomes were identical to what they would have been if operated at the start. No cure window was lost by waiting.)

Elena absorbed this. She had read the data before but was hearing it framed differently. “¿Y la crítica de que los datos son japoneses?” she asked. (And the criticism that the data are Japanese?)

“Es una crítica legítima, y las guías de la ATA 2022 la reconocen,” Diego acknowledged. “Los datos de validación en poblaciones norteamericanas son más limitados pero consistentes — el grupo de Haugen y la Universidad de California y la Mayo Clinic han publicado series de seguimiento activo con el mismo patrón de baja progresión y mortalidad cero. La 2022 ATA guideline formalmente incluyó el seguimiento activo como estrategia aceptable para el microcarcinoma papilar de bajo riesgo, reconociendo explícitamente que la mortalidad del cáncer no operado es menor que la morbilidad de la cirugía en este grupo específico.” (It is a legitimate criticism, and the 2022 ATA guidelines acknowledge it. The validation data in North American populations is more limited but consistent — the Haugen group and the University of California and Mayo Clinic have published active surveillance series with the same pattern of low progression and zero mortality. The 2022 ATA guideline formally included active surveillance as an acceptable strategy for low-risk papillary microcarcinoma, explicitly recognizing that mortality from untreated cancer is lower than surgical morbidity in this specific group.)

He turned to the surgical risk argument, which he expected to land differently with a clinician. Hemithyroidectomy for an 8mm left lobe PMC would involve removal of the left thyroid lobe and isthmus. Recurrent laryngeal nerve injury during hemithyroidectomy — producing hoarseness, voice weakness, or in severe cases aspiration — occurs as a permanent complication in 0.5 to 2 percent of cases in experienced hands. Permanent hypoparathyroidism (from inadvertent removal of or injury to a parathyroid gland) occurs in 0.5 to 2 percent of hemithyroidectomies, requiring lifelong calcium and calcitriol supplementation and monitoring. If Elena later required completion thyroidectomy for a contralateral thyroid problem, the recurrent risks would compound.

“Como radióloga, usted sabe que el 0.5 al 2 porciento no es insignificante cuando el beneficio contra el cual se mide es cero muertes específicas por cáncer en 10 años,” Diego said. “El riesgo de daño permanente de la voz o del calcio con la cirugía es real. El riesgo de morir de este cáncer específico con seguimiento activo es prácticamente cero. El argumento para operar es que el seguimiento activo requiere adherencia — usted tiene que volver para los ultrasonidos. El argumento para no operar es que la probabilidad de perjuicio de la cirugía supera la probabilidad de beneficio de la cirugía en este diagnóstico específico.” (As a radiologist, you know that 0.5 to 2 percent is not insignificant when the benefit against which it is measured is zero cancer-specific deaths in 10 years. The risk of permanent voice or calcium damage with surgery is real. The risk of dying from this specific cancer with active surveillance is essentially zero. The argument for operating is that active surveillance requires adherence — you have to come back for the ultrasounds. The argument for not operating is that the probability of harm from surgery exceeds the probability of benefit from surgery in this specific diagnosis.)

Elena was quiet for a moment. Then, pragmatically: “¿Con qué frecuencia los ultrasonidos?” (How often the ultrasounds?)

“Cada seis meses el primer año, luego anual si no hay cambios. Usted como radióloga puede leer sus propias imágenes — eso tiene valor. Los criterios de escalada son claros: crecimiento de 3 milímetros o más, ganglios nuevos con características sospechosas en el ultrasonido. Si cualquiera de esos dos ocurre, va directo a cirugía sin demora.” (Every six months the first year, then annually if no changes. As a radiologist you can read your own images — that has value. The escalation criteria are clear: growth of 3 millimeters or more, new lymph nodes with suspicious characteristics on ultrasound. If either of those occurs, straight to surgery without delay.)

Elena agreed to active surveillance. She noted, with a small irony, that she had ordered hundreds of TIRADS 5 biopsies in her career and this was the first time the result directly concerned her own thyroid. At six months, the nodule measured 8 millimeters — unchanged. At twelve months, 8 millimeters. At two years, 7 millimeters. She remained on surveillance. She told Diego at the two-year visit: “Lo más difícil no fue la ciencia. Fue el instinto. Sabía los datos, pero el instinto de médico dice que el cáncer se opera. Tardé tres meses en aceptar que en este diagnóstico específico, el instinto estaba equivocado.” (The hardest part was not the science. It was the instinct. I knew the data, but the physician instinct says cancer is operated on. It took me three months to accept that in this specific diagnosis, the instinct was wrong.)

Key phrases for papillary thyroid microcarcinoma active surveillance conversations

• “El microcarcinoma papilar de tiroides tiene un comportamiento muy diferente a la mayoría de los cánceres. En Japón siguieron a más de 1,200 pacientes durante hasta 25 años — ninguno murió del cáncer de tiroides.” (Papillary thyroid microcarcinoma has very different behavior from most cancers. In Japan, more than 1,200 patients were followed for up to 25 years — none died of thyroid cancer.)
• “La cirugía tiene riesgo real de daño permanente al nervio de la voz y a las glándulas del calcio. Para este cáncer específico, esos riesgos son mayores que el beneficio de operar ahora.” (Surgery has real risk of permanent damage to the voice nerve and the calcium glands. For this specific cancer, those risks are greater than the benefit of operating now.)
• “El seguimiento activo no es ignorar el cáncer. Es un protocolo específico con ultrasonido cada seis meses y criterios claros de cuándo operamos.” (Active surveillance is not ignoring the cancer. It is a specific protocol with ultrasound every six months and clear criteria for when we operate.)
• “El 3.8 porciento de los pacientes tuvieron crecimiento del tumor y se operaron. Los resultados de cirugía en ese grupo fueron iguales que si se hubieran operado al inicio. No se pierde la ventana de curación por esperar.” (3.8 percent of patients had tumor growth and were operated. Surgical outcomes in that group were the same as if they had been operated at the start. The cure window is not lost by waiting.)
• “Las guías de la ATA de 2022 reconocen el seguimiento activo como estrategia aceptable para este diagnóstico específico. No es una práctica experimental.” (The 2022 ATA guidelines recognize active surveillance as an acceptable strategy for this specific diagnosis. It is not experimental practice.)

Scenario 3: Roberto Salinas — 62, retired Spanish teacher from San Diego, T3N0M0 glottic squamous cell carcinoma

Roberto Salinas is sixty-two years old, a retired high school Spanish teacher from San Diego who taught Spanish language and literature for thirty-one years at a public school in the Barrio Logan neighborhood. He is a former smoker — forty pack-years, quit two years ago when his youngest grandchild was born. He presented to his primary care physician with a four-month history of progressive hoarseness that his wife Carmela had first noticed during a family dinner (“Tu voz ya no suena como tú” — “Your voice no longer sounds like you”). Flexible laryngoscopy by an otolaryngologist showed a 2.8 centimeter transglottic mass involving the left true vocal cord with cord fixation — the left vocal cord did not move on inspiration, indicating involvement of the cricoarytenoid musculature or the recurrent laryngeal nerve. CT of the neck and chest confirmed the glottic primary with no regional lymphadenopathy and no distant metastases. Biopsy returned squamous cell carcinoma. He was staged T3N0M0 (Stage III) and referred to head and neck oncology.

At the head and neck oncology clinic, Carmela had been on the internet since the day of the laryngoscopy. She had read about total laryngectomy — she understood what it meant. She had also read about laser surgery, about robotic surgery, about radiation. She arrived prepared and scared in equal measure. When the head and neck oncology team recommended concurrent cisplatin plus IMRT — seven weeks of daily radiotherapy concurrent with weekly cisplatin 40 mg/m² — without surgery, Carmela could not accept it.

“Tengo miedo de que dejen el tumor ahí,” she told nurse Ana López. “¿Cómo saben que la radiación lo mató si no lo quitan? Con la laringectomía lo sacan y lo mandan a patología y ya no está.” (I am afraid they are leaving the tumor there. How do they know the radiation killed it if they don’t remove it? With laryngectomy they take it out and send it to pathology and it’s no longer there.)

Ana understood the source of Carmela’s fear. The surgical model of cancer treatment — remove, confirm, done — has an intuitive completeness that radiation does not. Radiation is invisible. You cannot hold it, count it, or see the specimen under the microscope after it is done. You wait and you image and you scope.

“Su miedo tiene sentido,” Ana said. “La cirugía da una sensación de certeza que la radiación no da visualmente. Quiero explicarle dos cosas: qué muestra la evidencia sobre los resultados, y qué significa la laringectomía total para la vida de su esposo.” (Your fear makes sense. Surgery gives a sense of certainty that radiation does not give visually. I want to explain two things: what the evidence shows about outcomes, and what total laryngectomy means for your husband’s life.)

She opened with the VA Laryngeal Cancer Study Group trial — the landmark 1991 study that established organ-preservation chemoradiation for laryngeal cancer. The Veterans Affairs Cooperative Studies Program, building on the observation that cisplatin plus 5-fluorouracil (5-FU) caused regression of laryngeal tumors in patients treated for inoperable disease, designed a randomized trial: 332 patients with resectable Stage III or IV laryngeal cancer were randomized to either induction cisplatin plus 5-FU followed by radiation, or to total laryngectomy plus adjuvant radiation (the standard of care at the time). The primary endpoint was larynx preservation. The secondary endpoint was overall survival.

The results, published in the New England Journal of Medicine in 1991, were striking: two-year overall survival was 68 percent in both arms — identical. Cancer-specific survival was equivalent. But 64 percent of patients in the chemotherapy plus radiation arm retained their larynx at two years — they were alive, cancer-free, and still speaking through their own vocal cords. The conclusion: organ preservation with chemotherapy plus radiation did not cost lives compared with laryngectomy. It saved voices.

“Este estudio comparó directamente lo que estamos discutiendo,” Ana said. “332 pacientes con cáncer de laringe del mismo estadio que su esposo. La mitad tuvo laringectomía total más radioterapia — la cirugía más definitiva. La otra mitad tuvo quimioterapia más radioterapia. La supervivencia a dos años fue 68 porciento en los dos grupos — idéntica. Pero el 64 porciento de los pacientes que recibieron quimio y radiación mantuvieron su laringe. Mantuvieron su voz.” (This study directly compared what we are discussing. 332 patients with laryngeal cancer at the same stage as your husband. Half had total laryngectomy plus radiotherapy — the most definitive surgery. The other half had chemotherapy plus radiotherapy. Two-year survival was 68 percent in both groups — identical. But 64 percent of patients who received chemo and radiation kept their larynx. They kept their voice.)

She walked through RTOG 91-11, the trial that refined the organ-preservation approach. Published in the New England Journal of Medicine in 2003, RTOG 91-11 compared three arms: induction cisplatin/5-FU followed by radiation (the VA Study approach), concurrent cisplatin plus radiation (weekly cisplatin during the radiation course), and radiation alone. The concurrent cisplatin plus radiation arm achieved the best larynx preservation: 88 percent at two years, compared with 75 percent for induction and 70 percent for radiation alone. Concurrent cisplatin plus radiation also achieved superior locoregional control compared with the other arms. This established concurrent chemoradiation as the standard organ-preservation approach — which is exactly what Roberto’s team recommended.

“El estudio RTOG 91-11 luego mostró que el cisplatino dado durante la radioterapia — el tratamiento de su esposo — logra el 88 porciento de preservación de laringe a dos años. Ese es el estándar de cuidado actual para el estadio de su esposo.” (The RTOG 91-11 trial then showed that cisplatin given during radiotherapy — your husband’s treatment — achieves 88 percent larynx preservation at two years. That is the current standard of care for your husband’s stage.)

Carmela’s question came back: “Pero ¿cómo saben que el tratamiento funcionó?” (But how do they know the treatment worked?)

Ana explained the response assessment protocol. Eight to twelve weeks after the last day of radiation — once the acute mucosal inflammation from treatment has resolved sufficiently — Roberto would undergo a PET-CT scan (which detects metabolically active cancer by tracking glucose uptake) and direct laryngoscopy under anesthesia (which allows the head and neck surgeon to visually inspect the larynx and take biopsies of any residual tissue that looks abnormal). A complete response on PET-CT plus a negative laryngoscopy biopsy means the tumor has been controlled. Roberto would then enter surveillance with laryngoscopy every three months in year one, every six months in year two, and annually thereafter.

“Si la evaluación a las ocho a doce semanas muestra enfermedad residual — si el tratamiento no controló completamente el tumor — la laringectomía de rescate sigue siendo posible,” Ana said. “No perdemos la opción quirúrgica si la radiación no funciona. Empezamos con el tratamiento que tiene la misma supervivencia y que puede mantener la laringe, y si necesitamos la cirugía, la hacemos entonces. No de manera preventiva.” (If the assessment at eight to twelve weeks shows residual disease — if the treatment did not completely control the tumor — salvage laryngectomy is still possible. We do not lose the surgical option if the radiation does not work. We start with the treatment that has the same survival and that can keep the larynx, and if we need surgery, we do it then. Not preemptively.)

Then Ana turned to the functional question — what total laryngectomy actually means, which she explained not to discourage surgery but because Carmela’s model of laryngectomy as “removing the tumor and it’s done” was incomplete. Total laryngectomy removes the larynx entirely: the vocal folds, the arytenoids, the epiglottis, the hyoid, and the adjacent muscular structures. The trachea is divided and the upper tracheal stump is sutured to an opening in the front of the neck — a permanent stoma. Roberto would breathe exclusively through this stoma for the rest of his life. He would no longer breathe through his nose or his mouth. He could no longer swim (water entering the stoma enters directly into the lungs). His sense of smell and the humidification and warming of inhaled air through nasal breathing would be altered permanently unless he used a heat-and-moisture exchange filter over the stoma. His natural voice would be permanently absent. Voice rehabilitation after laryngectomy involves three options: tracheoesophageal puncture (a surgically created fistula between the trachea and esophagus through which a voice prosthesis is inserted — the patient covers the stoma and air is shunted through the prosthesis to produce esophageal vibration that can be shaped into speech), an electrolarynx device held to the neck (producing mechanical vibration that the patient shapes with the mouth), or esophageal speech (learning to trap and release air from the esophagus, a technique that takes months to acquire). All three methods produce functional communication, but none produces the patient’s natural voice.

“Su esposo enseñó español treinta y un años,” Ana said. “Su voz fue su herramienta de trabajo durante toda su carrera. Esa voz — la suya, la que Carmela reconoce cuando él habla — puede mantenerse si el tratamiento funciona. La quimiorradioterapia le da esa posibilidad con la misma supervivencia que la cirugía. Si empezamos con la laringectomía, esa posibilidad ya no existe.” (Your husband taught Spanish for thirty-one years. His voice was his working tool for his entire career. That voice — his, the one Carmela recognizes when he speaks — can be maintained if the treatment works. Chemoradiotherapy gives him that possibility with the same survival as surgery. If we start with laryngectomy, that possibility no longer exists.)

Carmela was quiet for a long time. Roberto reached for her hand. “Yo quiero intentar conservar la voz,” he said. “Si la radiación no funciona, tendremos que operar. Pero quiero intentarlo.” (I want to try to preserve the voice. If the radiation does not work, we will have to operate. But I want to try.)

Roberto completed seven weeks of concurrent cisplatin and IMRT. The treatment was difficult: mucositis in weeks five through seven required fentanyl lozenges and a gastrostomy tube for two weeks. At twelve-week PET-CT, there was no evidence of residual metabolically active disease. Direct laryngoscopy showed complete clinical response. At one-year surveillance laryngoscopy, the left vocal cord remained fixed — the radiation had not restored mobility — but no residual tumor was visible and biopsies were negative. His voice was hoarse but present and fully comprehensible. He returned to teaching a one-semester volunteer Spanish conversation course at a community center in his retirement. At his two-year visit, still no evidence of recurrence. Carmela brought a photograph of him at the community center, speaking to a group of a dozen students. “Sigue sonando como él,” she told Ana. (He still sounds like himself.)

Key phrases for laryngeal cancer organ-preservation conversations

• “El estudio de la Administración de Veteranos comparó directamente la laringectomía con la quimiorradioterapia en 332 pacientes. La supervivencia fue idéntica — 68 porciento en los dos grupos. Pero el 64 porciento de los pacientes con quimiorradioterapia mantuvieron la laringe.” (The Veterans Administration study directly compared laryngectomy with chemoradiotherapy in 332 patients. Survival was identical — 68 percent in both groups. But 64 percent of patients with chemoradiotherapy kept the larynx.)
• “La laringectomía total significa un agujero permanente en el cuello para respirar y pérdida permanente de la voz natural. La quimiorradioterapia da la misma supervivencia con la posibilidad de mantener la voz.” (Total laryngectomy means a permanent hole in the neck for breathing and permanent loss of the natural voice. Chemoradiotherapy gives the same survival with the possibility of keeping the voice.)
• “A las ocho a doce semanas del tratamiento, hacemos un PET-CT y una laringoscopia directa para confirmar que el tumor respondió. Si hay enfermedad residual, la laringectomía de rescate sigue siendo posible.” (Eight to twelve weeks after treatment, we do a PET-CT and direct laryngoscopy to confirm the tumor responded. If there is residual disease, salvage laryngectomy is still possible.)
• “El RTOG 91-11 mostró que el cisplatino concurrente con radioterapia logra el 88 porciento de preservación de laringe a dos años. Es el estándar actual para el estadio de su esposo.” (RTOG 91-11 showed that concurrent cisplatin with radiotherapy achieves 88 percent larynx preservation at two years. It is the current standard for your husband’s stage.)
• “Empezamos con el tratamiento que puede mantener la laringe. La cirugía de rescate queda disponible si la necesitamos. No perdemos la opción quirúrgica — la posponemos solo si no la necesitamos.” (We start with the treatment that can keep the larynx. Salvage surgery remains available if we need it. We do not lose the surgical option — we defer it only if we do not need it.)
• “Después del tratamiento, la voz puede quedar con ronquera. El tumor puede haber dejado daño en las cuerdas. Pero la voz de su esposo — reconocible, su propia voz — tiene posibilidad de mantenerse. Con la laringectomía, esa posibilidad no existe.” (After treatment, the voice may remain hoarse. The tumor may have left damage to the cords. But your husband’s voice — recognizable, his own voice — has a chance of being maintained. With laryngectomy, that chance does not exist.)

Six practical Spanish phrases for head and neck oncology clinic conversations

1. “El cáncer de garganta causado por el VPH es muy sensible a la radioterapia. El estudio ORATOR2 mostró que la radioterapia da la misma supervivencia que la cirugía, pero los pacientes reportaron mejor función para tragar a los dos años.” (HPV-caused throat cancer is very sensitive to radiotherapy. The ORATOR2 study showed radiotherapy gives the same survival as surgery, but patients reported better swallowing function at two years.) — For HPV-positive oropharyngeal cancer patients who expected surgical removal of the tumor.
2. “El VPH es muy común en adultos. No es posible saber cuándo se adquirió. No dice nada sobre la fidelidad de nadie.” (HPV is very common in adults. It is not possible to know when it was acquired. It says nothing about anyone’s fidelity.) — For preempting or addressing HPV stigma in oropharyngeal cancer conversations.
3. “El microcarcinoma papilar de tiroides tiene mortalidad específica prácticamente cero con seguimiento activo. La cirugía tiene un riesgo real de daño permanente a la voz y al calcio que supera el beneficio en este diagnóstico.” (Papillary thyroid microcarcinoma has essentially zero cancer-specific mortality with active surveillance. Surgery has a real risk of permanent voice and calcium damage that exceeds the benefit in this diagnosis.) — For thyroid cancer patients who cannot understand why surgery is not recommended immediately.
4. “El seguimiento activo del microcarcinoma de tiroides no es ignorar el cáncer. Es ultrasonido cada seis meses con criterios claros de cuándo operamos. Los que tuvieron progresión y se operaron tuvieron los mismos resultados que si se hubieran operado al inicio.” (Active surveillance of thyroid microcarcinoma is not ignoring the cancer. It is ultrasound every six months with clear criteria for when we operate. Those who had progression and were operated had the same outcomes as if they had been operated at the start.) — For families who fear that surveillance delays treatment to the point of losing the cure window.
5. “El estudio de la Administración de Veteranos mostró supervivencia idéntica entre laringectomía y quimiorradioterapia en 332 pacientes. El 64 porciento de los que recibieron quimiorradioterapia mantuvieron la laringe y la voz.” (The Veterans Administration study showed identical survival between laryngectomy and chemoradiotherapy in 332 patients. 64 percent of those who received chemoradiotherapy kept the larynx and voice.) — For laryngeal cancer families who insist surgery is more definitive than radiation.
6. “Si la quimiorradioterapia no controla el tumor completamente, la laringectomía de rescate sigue siendo posible. Empezamos con el tratamiento que puede mantener la voz y usamos la cirugía si la necesitamos, no de manera preventiva.” (If chemoradiotherapy does not completely control the tumor, salvage laryngectomy is still possible. We start with the treatment that can maintain the voice and use surgery if we need it, not preemptively.) — For families who cannot accept the uncertainty of radiation response without surgical confirmation.

FAQ: Head and neck oncology clinic Spanish conversations

How do I explain to a Spanish-speaking patient with HPV-positive oropharyngeal cancer why concurrent chemoradiation is recommended over surgery when the tonsil tumor is visible on laryngoscopy?

The key is the biological argument (HPV-positive tumors are exquisitely radiosensitive) plus the ORATOR2 finding (equivalent survival, better swallowing). For a patient with nodal disease, adding the combined-treatment argument completes the explanation: surgery alone requires adjuvant radiation for nodal disease, meaning the patient receives both surgery and radiation with compounded morbidity but without survival benefit. In Spanish: “El cáncer de garganta causado por el VPH es muy sensible a la radiación — el virus hace que las células del tumor no puedan reparar el daño del ADN que la radiación produce. El ORATOR2 mostró que la radioterapia da la misma supervivencia que la cirugía robótica, pero los pacientes reportaron mejor función para tragar a los dos años. Con sus ganglios, la cirugía sola no sería completa — necesitaría radioterapia después. Eso son dos tratamientos con sus morbilidades respectivas. La radioterapia sola llega a la misma supervivencia sin sumar la cirugía.”

What is the Kuma Hospital data and why does it change the recommendation for papillary thyroid microcarcinoma?

Dr. Akira Miyauchi and Dr. Yasuhiro Ito at Kuma Hospital in Osaka enrolled 1,235 patients with low-risk papillary thyroid microcarcinoma (≤1 cm, no extrathyroidal extension, no suspicious lymph nodes, not adjacent to the recurrent laryngeal nerve) in an active surveillance protocol beginning in 1993. At 10-year follow-up: 3.8% had size progression ≥3mm (and proceeded to surgery with equivalent outcomes to immediate surgery), 1.7% developed new clinical nodal metastases, 0 patients developed distant metastases, and 0 patients died of thyroid cancer. The key implication: cancer-specific mortality from low-risk PMC with surveillance is essentially zero, while hemithyroidectomy carries 0.5–2% risk of permanent recurrent laryngeal nerve injury and 0.5–2% risk of permanent hypoparathyroidism. The 2022 ATA guidelines formally endorsed active surveillance as an acceptable alternative to immediate thyroidectomy for this specific population. In Spanish: “El Hospital Kuma siguió a 1,200 pacientes con este cáncer durante hasta 25 años. Ninguno murió del cáncer de tiroides. La cirugía tiene riesgo de daño permanente a la voz y al calcio. Para este cáncer específico, los riesgos quirúrgicos superan el beneficio de operar. Eso cambió las guías de la ATA en 2022.”

Why is total laryngectomy not the recommended treatment for resectable T3 glottic laryngeal cancer, and how does the VA Laryngeal Cancer Study support organ preservation?

The VA Laryngeal Cancer Study Group (NEJM 1991) randomized 332 patients with resectable Stage III-IV laryngeal cancer to induction cisplatin/5-FU + radiation versus total laryngectomy + adjuvant radiation. Two-year overall survival was identical (68% vs 68%) with 64% larynx preservation in the chemotherapy arm. RTOG 91-11 (NEJM 2003) established concurrent cisplatin + radiation as superior to the induction approach, achieving 88% larynx preservation at 2 years. If chemoradiation fails to achieve complete response at 8–12 week response assessment (PET-CT + direct laryngoscopy), salvage laryngectomy is still possible without compromising the outcomes of surgery performed after radiation failure. The functional argument: total laryngectomy creates a permanent tracheostomy, permanently eliminates nasal breathing, and permanently removes the natural voice — outcomes of direct significance for a patient who has used his voice professionally. In Spanish: “Los datos del estudio VA y el RTOG 91-11 muestran supervivencia idéntica entre la laringectomía y la quimiorradioterapia. El 88 porciento de los pacientes con quimiorradioterapia mantuvieron la laringe. Si el tratamiento no funciona, la cirugía de rescate sigue siendo posible. La laringectomía es permanente — la radiación nos da la posibilidad de evitarla.”

How should head and neck oncology nurses address HPV stigma directly when talking with Spanish-speaking families of oropharyngeal cancer patients?

HPV stigma in oropharyngeal cancer — the implicit or explicit assumption that the diagnosis implies infidelity — can prevent full family engagement with the treatment plan if it is not directly addressed. The most effective approach is preemptive: raise the topic before the family does, normalize it explicitly, and provide the accurate clinical frame. Key statements: HPV is ubiquitous (>80% of sexually active US adults have had some HPV type); oropharyngeal HPV can persist latently for 20–30 years before driving malignant transformation; it is not possible to establish when or from whom it was acquired; and the diagnosis says nothing about fidelity. In Spanish: “Muchas parejas preguntan lo que el VPH significa para su relación. Quiero decirlo claramente: el VPH es muy común — la mayoría de los adultos en los Estados Unidos han tenido algún tipo en algún momento. El virus puede quedarse en el cuerpo por décadas. No es posible saber cuándo ni cómo se adquirió. El cáncer de garganta por VPH no dice nada sobre la fidelidad de nadie. Lo digo porque es cierto, y porque quiero que esa pregunta no interfiera con el tratamiento.” After this framing, briefly mention age-appropriate HPV vaccination for children and young adult family members via their own primary care provider.

How do head and neck oncology clinic nurses approach Spanish-speaking family members who cannot accept the uncertainty of radiation response — who want the tumor surgically removed for confirmation that it is gone?

This fear is rational: surgery produces a specimen, a pathology report, a confirmed negative margin. Radiation produces a response assessment at 8–12 weeks — an image, a scope, a biopsy of what remains. The uncertainty is real and the nurse must acknowledge it rather than dismiss it. Two arguments help. First, the response assessment protocol is rigorous: PET-CT plus direct laryngoscopy with biopsy at 8–12 weeks provides the same clinical information that surgical pathology would provide, with the key difference that it is done after the treatment works rather than during it. Second, the salvage surgery option means the family is not choosing between radiation and surgery — they are choosing the order of operations. In Spanish: “A las ocho a doce semanas del final de la radiación, hacemos un PET-CT y una laringoscopia directa con biopsia. Eso nos dice si el tumor respondió completamente — es la misma información que daría la cirugía, solo que después del tratamiento que puede salvar la voz. Y si la respuesta no es completa, la laringectomía de rescate sigue siendo posible, con los mismos resultados que si hubiéramos operado desde el principio. No estamos apostando contra la cirugía. Estamos dándole al señor Salinas la posibilidad de no necesitarla.”